Determinants of interindividual variability and extent of CYP2D6 and CYP1A2 inhibition by paroxetine and fluvoxamine in vitro

Journal of Clinical Psychopharmacology

Volumn 18, Issue 3, 1998, Pages 198-207

  Özdemir, Vural ^b   Naranjo, Claudio A ^a   Shulman, Richard W ^b   Herrmann, Nathan ^b   Sellers, Edward M ^b   Reed, Ken ^b   Kalow, Werner ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ATENOLOL; CAFFEINE; CETIRIZINE; CONTAC COUGHCAPS DM; CROMOGLYCATE DISODIUM; CYTOCHROME P450 1A2; CYTOCHROME P450 2D6; DEXTROMETHORPHAN; DICLOFENAC; ENZYME INHIBITOR; FERROUS FUMARATE; FLUVOXAMINE; FLUVOXAMINE MALEATE; LORATADINE; LORAZEPAM; METOPROLOL; PARACETAMOL; PAROXETINE; SALBUTAMOL; TAMOXIFEN; TEMAZEPAM; UNCLASSIFIED DRUG; WAKE UPS;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG BLOOD LEVEL; DRUG INHIBITION; DRUG TRANSFORMATION; DRUG URINE LEVEL; ENZYME INHIBITION; FEMALE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PATIENT CODING; PRIORITY JOURNAL; PSYCHIATRIC TREATMENT;

ADULT; AGED; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CAFFEINE; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP2D6; DEXTROMETHORPHAN; FEMALE; FLUVOXAMINE; HUMANS; MALE; PAROXETINE; SEROTONIN UPTAKE INHIBITORS;

EID: 0031803047     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199806000-00004     Document Type: Article

References (59)

1. Keller MB, Lavori PW, Mueller TI, Endicott J, Coryell W, Hirschfeld RM, Shea T. Time to recovery, chronicity, and levels of psychopathology in major depression. A 5-year prospective follow-up of 431 subjects. Arch Gen Psychiatry 1992;49:809-16.
2. Preskorn SH. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokinet 1997;32[suppl 1]:1-21.
3. Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 1992;34:262-5.
4. Brøsen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 1993;45:1211-4.
5. Rasmussen BB, Mäenpää J, Pelkonen O, Loft S, Poulsen HE, Lykkesfeldt J, Brøsen K. Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine. Br J Clin Pharmacol 1995;39:151-9.
6. von Moltke LL, Greenblatt DJ, Court MH, Duan SX, Harmatz JS, Shader RI. Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants. J Clin Psychopharmacol 1995;15:125-31.
7. von Moltke LL, Greenblatt DJ, Duan SX, Schmider J, Kudchadker L, Fogelman SM, Harmatz JS, Shader RI. Phenacetin O-deethylation by human liver microsomes in vitro: inhibition by chemical probes, SSRI antidepressants, nefazodone and venlafaxine. Psychopharmacology 1996;128:398-407.
8. Eichelbaum M, Gross AS. The genetic polymorphism of debrisoquine/sparteine metabolism-clinical aspects. Pharmacol Ther 1990;46:377-94.
9. Brøsen K. Are pharmacokinetic drug interactions with the SSRIs an issue? Int Clin Psychopharmacol 1996;11[suppl 1]:23-7.
10. Aoyama T, Korzekwa K, Nagata K, Gillette J, Gelboin HV, Gonzalez FJ. Estradiol metabolism by complementary deoxyribonucleic acid-expressed human cytochrome P450s. Endocrinology 1990;126:3101-6.
11. Guengerich FP, Shimada T. Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. Chem Res Toxicol 1991;4:391-107.
12. Eaton DL, Gallagher EP, Bammler TK, Kunze KL. Role of cytochrome P4501A2 in chemical carcinogenesis: implications for human variability in expression and enzyme activity. Pharmacogenetics 1995;5:259-74.
13. Jeppesen U, Gram LF, Vistisen K, Loft S, Poulsen HE, Brøsen K. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol 1996;51:73-8.
14. Tang B-K, Kalow W. Assays for CYP1A2 by testing in vivo metabolism of caffeine in humans. Methods Enzymol 1996;272: 124-31.
15. Denaro CP, Wilson M, Jacob P, Benowitz NL Validation of urine caffeine metabolite ratios with use of stable isotope-labeled caffeine clearance. Clin Pharmacol Ther 1996;59:284-96.
16. Jeppesen U, Loft S, Poulsen HE, Brøsen K. A fluvoxamine-caffeine interaction study. Pharmacogenetics 1996;6:213-22.
17. Tang B-K, Zhou Y, Kadar D, Kalow W. Caffeine as a probe for CYP1A2 activity: potential influence of renal factors on urinary phenotypic trait measurements. Pharmacogenetics 1994;4:117-24.
18. Sindrup SH, Brøsen K, Gram LF, Hallas J, Skjelbo E, Allan A, Allen GD, Cooper SM, Mellows G, Tasker TCG, Zussman BD. The relationship between paroxetine and the sparteine oxidation polymorphism. Clin Pharmacol Ther 1992;51:278-87.
19. Brøsen K, Hansen JG, Nielsen KK, Sindrup SH, Gram LF. Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. Eur J Clin Pharmacol 1993;44:349-55.
20. Alderman J, Preskorn SH, Greenblatt DJ, Harrison W, Penenberg D, Allison J, Chung M. Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. J Clin Psychopharmacol 1997;17:284-91.
21. Özdemir V, Naranjo CA, Herrmann N, Reed K, Sellers EM, Kalow W. Paroxetine potentiates the central nervous system side-effects of perphenazine: contribution of cytochrome P450 2D6 inhibition in vivo. Clin Pharmacol Ther 1997;62:334-47.
22. Spina E, Pollicino AM, Avenoso A, Campo GM, Perucca E, Caputi AP. Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects. Ther Drug Monit 1993;15: 243-6.
23. Vandel S, Bertschy G, Baumann P, Bouquet S, Bonin B, Francois T, Sechter D, Bizouard P. Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. Pharmacol Res 1995;31:347-53.
24. Otton SV, Wu D, Joffe RT, Cheung SW, Sellers EM. Inhibition by fluoxetine of cytochrome P450 2D6 activity. Clin Pharmacol Ther 1993;53:401-9.
25. Kalow W, Tang B-K. Caffeine as a metabolic probe: exploration of the enzyme-inducing effect of cigarette smoking. Clin Pharmacol Ther 1991;49:44-8.
26. Ware JE, Sherbourne D. The MOS 36-item short-form health survey (SF-36). Conceptual framework and item selection. Med Care 1992;30:473-83.
27. Tang BK, Zubovits T, Kalow W. Determination of acetylated caffeine metabolites by high-performance exclusion chromatography. J Chromatogr 1986;375:170-3.
28. Campbell ME, Spielberg SP, Kalow W. A urinary metabolite ratio that reflects systemic caffeine clearance. Clin Pharmacol Ther 1987;42:157-65.
29. Tang BK, Kadar D, Qian L, Iriah J, Yip J, Kalow W. Caffeine as a metabolic probe: validation of its use for acetylator phenotyping. Clin Pharmacol Ther 1991;49:648-57.
30. Kalow W, Tang B-K. The use of caffeine for enzyme assays: a critical appraisal. Clin Pharmacol Ther 1993;53:503-14.
31. Chen ZR, Somogyi AA, Bochner F. Simultaneous determination of dextromethorphan and three metabolites in plasma and urine using high-performance liquid chromatography with application to their disposition in man. Ther Drug Monit 1990;12:97-104.
32. Hartter S, Wetzel H, Hiemke C. Automated determination of fluvoxamine in plasma by column-switching high-performance liquid chromatography. Clin Chem 1992;38:2082-6.
33. SPSS [computer program]. Version 6.1.2 for Windows. Chicago, IL: SPSS Inc., 1995.
34. Fuhr U, Klittich K, Staib AH. Inhibitory effect of grapefruit juice and the active component naringenin on CYP1A2 dependent metabolism of caffeine in man. Br J Clin Pharmacol 1993;35:431-6.
35. Sindrup SH, Brøsen K, Gram LF. Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relationship to the sparteine oxidation polymorphism. Clin Pharmacol Ther 1992;51:288-95.
36. Celada P, Dolera M, Alvarez E, Artigas F. Effects of acute and chronic treatment with fluvoxamine on extracellular and platelet serotonin in the blood of major depressive patients. Relationship to clinical improvement. J Affect Dis 1992;25:243-50.
37. Caraco Y, Wilkinson GR, Wood AJJ. Differences between white subjects and Chinese subjects in the in vivo inhibition of cytochrome P450s 2C19, 2D6, and 3A by omeprazole. Clin Pharmacol Ther 1996;60:396-404.
38. Evans WE, Relling MV, Petros WP, Meyer WH, Mirro J, Crom WR. Dextromethorphan and caffeine as probes for simultaneous determination of debrisoquin-oxidation and N-acetylation phenotypes in children. Clin Pharmacol Ther 1989;45:568-73.
39. Sindrup SH, Brøsen K. The pharmacogenetics of codeine hypoalgesia. Pharmacogenetics 1995;5:335-46.
40. Popli AP, Baldessarini RJ, Cole JO. Interactions of serotonin reuptake inhibitors with tricyclic antidepressants. Arch Gen Psychiatry 1994;51:666-7.
41. Hiemke C, Weigmann H, Hartter S, Dahmen N, Wetzel H, Muller H. Elevated levels of clozapine in serum after addition of fluvoxamine. J Clin Psychopharmacol 1994;14:279-81.
42. Spina E, Campo GM, Avenoso A, Pollicino MA, Caputi AP. Interaction between fluvoxamine and imipramine/desipramine in four patients. Ther Drug Monit 1992;14:194-6.
43. Sperber AD. Interactions between fluvoxamine and sustained release theophylline in an 11-year old boy. Drug Saf 1991;6:460-2.
44. van den Brekel AM, Harrington L. Toxic effects of theophylline caused by fluvoxamine. Can Med Assoc J 1994;151:1289-90.
45. Winstead DK. Coffee consumption among psychiatric inpatients. Am J Psychiatry 1976;133:1447-50.
46. Charney DS, Heninger GR, Jatlow PI. Increased anxiogenic effects of caffeine in panic disorders. Arch Gen Psychiatry 1985; 42:233-43.
47. Dixon M, Webb EC, Thorne CJR, Tipton KF. Enzymes. 3rd ed. New York: Longman Group Limited, 1979:333-467.
48. von Moltke LL, Greenblatt DJ, Schmider J, Harmatz JS, Shader RI. Metabolism of drugs by cytochrome P450 3A isoforms. Clin Pharmacokinet 1995;29[suppl 1]:33-44.
49. Schmider J, Greenblatt DJ, von Moltke LL, Shader RI. Relationship of in vitro data on drug metabolism to in vivo pharmacokinetics and drug interactions: implications for diazepam disposition in humans. J Clin Psychopharmacol 1996;16:267-72.
50. Fleishaker JC, Hulst LK. A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine. Eur J Clin Pharmacol 1994;46:35-9.
51. Perucca E, Gatti G, Cipolla G, Spina E, Barel S, Soback S, Gips M, Bialer M. Inhibition of diazepam metabolism by fluvoxamine: a pharmacokinetic study in normal volunteers. Clin Pharmacol Ther 1994;56:471-6.
52. Jeppesen U, Rasmussen BB, Brøsen K. Fluvoxamine inhibits the CYP2C19-catalyzed bioactivation of chloroguanide. Clin Pharmacol Ther 1997;62:279-86.
53. Schmider J, Greenblatt DJ, von Moltke LL, Karsov D, Shader RI. Inhibition of CYP2C9 by selective serotonin reuptake inhibitors in vitro: studies of phenytoin p-hydroxylation. Br J Clin Pharmacol. 1997;44:495-8.
54. Leemann TD, Transon C, Bonnabry P, Dayer P. A major role for cytochrome P450TB (CYP2C subfamily) in the actions of nonsteroidal antiinflammatory drugs. Drugs Exp Clin Res 1993;19: 189-95.
55. Leemann T, Transon C, Dayer P. Cytochrome P450TB (CYP2C): a major monooxygenase catalyzing diclofenac 4′-hydroxylation in human liver. Life Sci 1993;52:29-34.
56. Shimada T, Iwasaki M, Martin MV, Guengerich FP. Human liver microsomal cytochrome P-450 enzymes involved in the bioactivation of procarcinogens detected by umu gene response in Salmonella typhimurium TA 1535/pSK1002. Cancer Res 1989; 49:3218-28.
57. Murray BP, Edwards RJ, Murray S, Singleton AM, Davies DS, Boobis AR. Human hepatic CYP1A1 and CYP1A2 content, determined with specific anti-peptide antibodies, correlates with the mutagenic activation of PhIP. Carcinogenesis 1993;14:585-92.
58. Boobis AR, Lynch AM, Murray S, de la Torre R, Solans A, Farré M, Segura J, Gooderham NJ, Davies DS. CYP1A2-catalyzed conversion of dietary heterocyclic amines to their proximate carcinogens is their major route of metabolism in humans. Cancer Res 1994;54:89-94.
59. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994;270:414-23.